These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

882 related articles for article (PubMed ID: 15112266)

  • 21. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
    Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
    J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
    Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma.
    Granfors T; Tomic R; Ljungberg B
    Scand J Urol Nephrol; 2009; 43(4):293-9. PubMed ID: 19363744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined-modality treatment and organ preservation in bladder cancer. Do molecular markers predict outcome?
    Weiss C; Rödel F; Wolf I; Papadopoulos T; Engehausen DG; Schrott KM; Sauer R; Rödel C
    Strahlenther Onkol; 2005 Apr; 181(4):213-22. PubMed ID: 15827690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p21WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer.
    Ahrendt SA; Brown HM; Komorowski RA; Zhu YR; Wilson SD; Erickson BA; Ritch PS; Pitt HA; Demeure MJ
    Surgery; 2000 Oct; 128(4):520-30. PubMed ID: 11015084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection.
    Kao JT; Chuah SK; Huang CC; Chen CL; Wang CC; Hung CH; Chen CH; Wang JH; Lu SN; Lee CM; Changchien CS; Hu TH
    Liver Int; 2007 Aug; 27(6):772-81. PubMed ID: 17617120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of lymph node density in predicting survival of patients with lymph node metastases after radical cystectomy: a multi-institutional study.
    Osawa T; Abe T; Shinohara N; Harabayashi T; Sazawa A; Kubota K; Matsuno Y; Shibata T; Shinno Y; Kamota S; Minami K; Sakashita S; Kumagai A; Mori T; Nonomura K
    Int J Urol; 2009 Mar; 16(3):274-8; discussion 278. PubMed ID: 19087211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome.
    Huang LW; Chou YY; Chao SL; Chen TJ; Lee TT
    Gynecol Oncol; 2001 Nov; 83(2):348-54. PubMed ID: 11606096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement.
    Frank I; Cheville JC; Blute ML; Lohse CM; Karnes RJ; Weaver AL; Sebo TJ; Nehra A; Zincke H
    Cancer; 2004 Oct; 101(8):1803-8. PubMed ID: 15386300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy.
    Jahnson S; Karlsson MG
    J Urol; 1998 Oct; 160(4):1291-6. PubMed ID: 9751338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
    Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
    Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
    Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
    Dekairelle AF; Tombal B; Cosyns JP; Gala JL
    Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
    Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
    Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder.
    Fleshner N; Kapusta L; Ezer D; Herschorn S; Klotz L
    J Urol; 2000 Oct; 164(4):1177-82. PubMed ID: 10992361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients.
    Goan YG; Hsu HK; Chang HC; Chou YP; Chiang KH; Cheng JT
    Ann Thorac Surg; 2005 Sep; 80(3):1007-16. PubMed ID: 16122475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
    Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C
    Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.